Home > Healthcare > Medical Devices > Diagnostic Devices > Point of Care Molecular Diagnostics Market

Point of Care Molecular Diagnostics Market Size

  • Report ID: GMI2210
  • Published Date: Jan 2023
  • Report Format: PDF

Point of Care Molecular Diagnostics Market Size

Point of Care Molecular Diagnostics Market size was valued at more than USD 38.5 billion in 2022 and is projected to grow substantially at over 8.5% growth rate from 2023 to 2032 owing to the increasing efforts for advancing diagnostic procedures.

 

R&D initiatives for improving diagnostic procedures for easy analysis of complex and severe diseases are foreseen to stimulate industry expansion. Moreover, the increasing number of favorable government programs supporting the development of molecular diagnostics owing to their medical, economic, and societal advantages are projected to augment point of care molecular diagnostics market revenues.

 

Complicated regulatory processes may slow down market progress

The business growth is hampered by complicated regulatory procedures such as pre- and post-market clearances and multiple clinical testing. For instance, the Clinical Laboratory Improvement Amendments (CLIA) rules mandate that the QC (Quality Control) for illness testing must be completed in accordance with the manufacturer’s instructions. In the absence of a specification from the manufacturer, the testing facility must establish a policy that adheres to acceptable laboratory procedures. However, with the growing awareness about the product’s benefits among buyers, the government may relax the requirements for adhering to strict laws, which is foreseen to benefit the market outlook.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for point of care molecular diagnostics was worth more than USD 38.5 billion in 2022 and is set to grow significantly at over 8.5% CAGR through 2032 driven by the increasing efforts for advancing diagnostic procedures.

Oncology segment is forecast to expand at over 9.5% CAGR between 2023 and 2032 owing to the rising prevalence of cancer and increasing healthcare expenditure.

Europe point of care molecular diagnostics market is projected to surpass USD 23 billion in revenue by 2032 due to the proliferation of molecular technology across major European countries.

Some of the top firms operating in the point of care molecular diagnostics industry are BioMerieux SA, Danaher Corporation, Bio-Rad Laboratories, Sysmex Corporation, Abaxis Inc, Roche Diagnostics, OraSure Technologies, Inc., and VIRCELL S.L. among others.

Point of Care Molecular Diagnostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 174
  • Countries covered: 26
  • Pages: 170
 Download Free Sample